This is a phase 2, multicenter, open-label study to evaluate the efficacy of abivertinib with abiraterone in patients with metastatic castration-resistant prostate cancer.

Start Date01 Sep 2025

Sponsor / Collaborator

Sorrento Therapeutics, Inc.

NCT06392841 / Not yet recruitingPhase 2

Hispanic/Latino and Non-Hispanic BlAck Patients Treated With niRaparib and Abiraterone Acetate Plus Prednisone for Metastatic hOrmone Sensitive Prostate Cancer With Deleterious Homologous recombinatioN Repair Alterations: a Phase II, Open Label studY

This is an open label, phase II trial in subjects with treatment naïve, metastatic hormone sensitive prostate cancer (mHSPC) with deleterious homologous recombination repair (HRR) alteration(s). These include pathologic alterations in BRCA 1/2, BRIP1, CHEK2, FANCA, PALB2, RAD51B, and/or RAD54L. A total of 64 people will be enrolled to the study.

Start Date01 Dec 2024

Sponsor / Collaborator

Hoosier Cancer Research Network

[+1]

100 Clinical Results associated with Abiraterone acetate

100 Translational Medicine associated with Abiraterone acetate

100 Patents (Medical) associated with Abiraterone acetate

2,934

Literatures (Medical) associated with Abiraterone acetate

01 Dec 2024·Molecular biology reports

Co-expression of Twist and Snai1: predictor of poor prognosis and biomarker of treatment resistance in untreated prostate cancer

Article

Author: Rammeh, Soumaya ; Hernández-Losa, Javier ; Zouari, Skander ; Moline, Teresa ; Said, Rahma ; Blel, Ahlem ; de Haro, Rosa Somoza Lopez ; Derouiche, Amine ; Ouerhani, Slah

BACKGROUND:

Prostate cancer (PCa) remains one of the most complex tumors in men. The assessment of gene expression is expected to have a profound impact on cancer diagnosis, prognosis, and treatment decisions. The aim of this study was to determine the utility of the epithelial-mesenchymal transition (EMT) transcription factors Twist and Snai1 in the treatment of naïve prostate cancer.

METHODS AND RESULTS:

We analyzed formalin-fixed paraffin-embedded (FFPE) prostate tissues from 108 PCa patients and 20 control biopsies using real-time quantitative reverse transcription-polymerase chain reaction (RT-qPCR) and 2^-ΔΔCt methods for Twist and Snail gene expression. The expression of Twist and Snai1 mRNA was significantly overexpressed in primary tissues of PCa patients compared with controls using ROC curve. Statistical analysis showed that the mRNAs of these two genes expression Snai1 and Twist were positively correlated with tumor development and prognostic parameters as Gleason score (p < 0.001; r = 0.707) and (p < 0.001; r = 0.627) respectively. The results of Kaplan-Meier analysis showed that mRNA expression of Snai1 and Twist genes expression were significant predictors of poor overall survival (OS) (Log rank p < 0.001) and progression-free survival (PFS) of patients (Log rank p < 0.001). Furthermore, our results showed that the expression of Snai1 and Twist genes expression in primary tissues of PCa patients could predict resistance to androgen deprivation therapy (p < 0.001) and resistance to the acidic drugs abiraterone or enzalutamide (p < 0.001). However, these two transcription factors failed to predict taxanes resistance at the time of diagnosis (p > 0.05).

CONCLUSION:

These results suggest that Snai1 and Twist are overexpressed during the onset and progression of PCa malignancies and may be theranostic markers of resistance to ADT, abiraterone, or enzalutamide therapy.

01 Feb 2024·Clinical case reports

An unusual presentation of metastatic prostate cancer in a 44‐year‐old man: A case report and review of the literature

Author: Kefayat, Amirhosein ; Ebrahimi, Pouya ; Nazari, Pedram ; Mahdavian, Abbas ; Taheri, Homa

Abstract:

Prostate cancer is one of the two most common non‐cutaneous cancers in men. Its presentation might be with unusual symptoms and cause the wrong initial diagnosis. This case report discusses a rare neurologic manifestation of advanced metastatic cancer in a low‐risk man. He had been receiving treatment for multiple sclerosis incorrectly due to unusual manifestations such as claudication and pelvic, leg, and shoulder pain. The patient underwent a whole‐body bone scan and then a transrectal ultrasound‐guided biopsy, which confirmed metastatic prostate cancer with a Gleason score between 7/10 and 10/10 in all samples. Following treatment with chemotherapeutic injections (docetaxel), luteinizing hormone‐releasing hormone (LHRH) analogous (Zoladex), and testosterone‐suppressing tablets (abiraterone), the disease has been under control and prostate‐specific antigen (PSA) level has decreased significantly. The most common sites of metastasis are regional lymph nodes, bones, and lungs. However, there are reports about the spread of this type of cancer to other parts of the body. Although most patients are diagnosed when the tumor is localized to the prostate, in about 25% of patients, the disease is diagnosed when metastasis has occurred. Some markers can assist physicians in the diagnosis of this disease, such as the Prostate Health Index and the 4 K score.

Key Clinical Message:

The diagnosis of prostate cancer should be considered in all age ranges of adult men. The long‐distance metastasis might cause unusual presentations of the disease, such as neurologic, musculoskeletal, and dermatologic symptoms and signs far from the origin of the cancer, before genitourinary manifestations. It is crucial to keep the diagnosis of prostate cancer in mind for men with suggestive signs and symptoms that are not usually detected in this disease.

01 Feb 2024·Cancer chemotherapy and pharmacology

Are novel oral oncolytics underdosed in obese patients?

Article

Author: Beijnen, Jos H ; van der Meer, Ellen K O ; Huitema, Alwin D R ; Lin, Lishi ; Steeghs, Neeltje

Abstract:

Purpose:

Data on the effects of obesity on drug exposure of oral targeted oncolytics is scarce. Therefore, the aim of this study was to investigate the influence of body weight and body mass index (BMI) on trough levels of oral oncolytics with an exposure–response relationship. The oral oncolytics of interest were abiraterone, alectinib, cabozantinib, crizotinib, imatinib, pazopanib, sunitinib and trametinib.

Methods:

This retrospective cohort study included patients treated with the selected oral oncolytics at the standard dose, with a measured trough level at steady state and with available body weight. The Spearman’s correlation test was used to determine the correlation between body weight and trough levels. The Fisher’s exact text was used to compare the frequency of inadequate trough levels between BMI categories.

Results:

1265 patients were included across the different oral oncolytics. A negative correlation coefficient was observed between weight and trough levels for crizotinib (n = 75), imatinib (n = 201) and trametinib (n = 310), respectively, ρ = − 0.41, ρ = − 0.24 and ρ = − 0.23, all with a p-value < 0.001. For crizotinib, a higher percentage of patients with a body weight > 100 kg had inadequate trough levels. No statistically significant differences were observed in the frequency of inadequate trough levels between BMI categories.

Conclusion:

Higher body weight was only correlated with lower plasma trough levels for crizotinib, imatinib, and trametinib. Therefore, patients with a high body weight may require dose escalation to obtain adequate target levels when treated with these oral oncolytics.

270

News (Medical) associated with Abiraterone acetate

30 May 2024

·www.globenewswire.com

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the fifth dose cohort of its Phase 1/2 study of ONCT-534 for the treatment of patients with metastatic castration-resistant prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). Patients in the fifth cohort are receiving ONCT-534, the company’s dual-action androgen receptor inhibitor (DAARI), at a dose of 600 mg taken orally once each day. The decision to proceed to this higher dose level was made by the study’s Safety Review Committee (SRC) after reviewing data from the fourth dose level of 300 mg ONCT-534 daily. An initial update on ONCT-534 safety and efficacy based on prostate-specific antigen (PSA) levels from this study is expected in the third quarter of 2024 and will include data from this 600 mg dose cohort. “We are encouraged by the rapid enrollment in the dose escalation portion of our Phase 1/2 study with ONCT-534. The drug has been well tolerated, with no dose limiting toxicities observed to date. We continue to open new sites and patient demand continues to be strong,” said Salim Yazji M.D., Chief Medical Officer at Oncternal Therapeutics. “We are looking forward to sharing initial safety and efficacy data soon, which will include a larger, more robust set of clinical and biomarker results, as well as longer follow-up from the initial dosing cohorts.” About Study ONCT-534-101Study ONCT-534-101 is a Phase 1/2, single-arm, open-label, multi-center study to evaluate the safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of ONCT-534 in patients with mCRPC who have relapsed or are refractory to approved ARPIs including enzalutamide, abiraterone, apalutamide, and darolutamide. After the safety and tolerability and preliminary antitumor activity of ONCT-534 have been assessed in Phase 1, Phase 2 will commence to further evaluate the safety and antitumor activity of ONCT-534 to support selecting an optimal dose. About Oncternal TherapeuticsOncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on hematological malignancies and prostate cancer. ONCT-534 is an investigational dual-action androgen receptor inhibitor (DAARI) with demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR aberration. It is a potential treatment for patients with mCRPC with unmet medical need because of resistance to androgen receptor pathway inhibitors, including those with AR amplification, mutations in the AR ligand binding domain (LBD), or splice variants with loss of the AR LBD. Study ONCT-534-101 (NCT05917470) has completed enrollment in four dose cohorts and continues to enroll and dose patients for treatment with mCRPC. ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) using the binding domain from zilovertamab. ONCT-808 has demonstrated activity in preclinical models against multiple hematological malignancies and solid tumors and has been shown to be specific for cancer cells expressing ROR1. Oncternal has developed a robust and reproducible manufacturing process that has the potential to reduce the time patients must wait for their individual CAR T therapy to be produced, compared with currently approved CAR T products. Oncternal has dosed patients under Study ONCT-808-101 (NCT05588440) with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of ROR1. Zilovertamab has been evaluated in a Phase 1/2 Study CIRM-0001 (NCT03088878) in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL), which resulted in 100% progression free survival (PFS) at 42 months in CLL patients expressing a p53 mutation/del(17p), a population underserved by current treatment options. Zilovertamab is also being evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (NCT05156905). More information on our company and programs is available at https://oncternal.com/. Forward-Looking InformationOncternal cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on Oncternal’s current beliefs and expectations. Forward-looking statements include statements regarding anticipated timing for study enrollment and announcing clinical data. Forward-looking statements are subject to risks and uncertainties inherent in Oncternal’s business, including risks associated with the clinical development and process for obtaining regulatory approval of Oncternal’s product candidates, such as potential delays in the commencement, enrollment and completion of clinical trials; the risk that interim results of a clinical trial do not predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, as follow-up on the outcome of any particular patient continues, and as more patient data become available; and other risks described in Oncternal’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Oncternal undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact Information: InvestorsRichard Vincent 858-434-1113rvincent@oncternal.com MediaCorey Davis, Ph.D. LifeSci Advisors 212-915-2577 cdavis@lifesciadvisors.com

Phase 1Clinical ResultImmunotherapyCell Therapy

29 May 2024

·www.prnewswire.com

ConcertAI: ASCO 2024 study uses ConcertAI Oncology Dataset to find earlier treatment with oliparib monotherapy may improve duration of therapy and overall survival

CAMBRIDGE, Mass., May 29, 2024 /PRNewswire/ -- ConcertAI, the leader in oncology predictive and generative AI SaaS and Real-World Data (RWD) Solutions for clinical research, announced the results of the study to be presented at the ASCO Annual Meeting 2024 utilizing its real-world oncology dataset. The study, conducted in cooperation with Merck & Co., Inc., and AstraZeneca, has found earlier treatment with oliparib monotherapy may improve duration of therapy and overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC). This real-world analysis indicates many mCRPC patients with homologous recombination repair gene mutation (HRRm) are receiving several lines of therapy prior to olaparib, even when novel hormonal agents (NHA) are used prior to mCRPC. HRRm+ patients with confirmed mCRPC diagnosis, age ≥21 years, treated with olaparib monotherapy (post May 19, 2020) and prior to abiraterone or enzalutamide were abstracted from electronic medical records in the ConcertAI Oncology Dataset with PC diagnosis between 1990 and 2023. Frequency of patients who progressed from metastatic hormone-sensitive PC (mHSPC) and from non-metastatic CRPC (nmCRPC) to mCRPC and treatment patterns prior to mCRPC were summarized. Jeff Elton, PhD, CEO of ConcertAI stressed, "This study underscores the potential of real-world data to support specific treatment decisions and improved patient outcomes. By analyzing our vast dataset of de-identified patient records, we were able to provide compelling evidence that earlier treatment with oliparib can significantly extend the duration of therapy and overall survival for patients with metastatic castration-resistant prostate cancer. This reinforces our core mission of transforming data housed in electronic health records into actionable insights that directly benefit patient care." This study will be presented at a poster session at the ASCO Annual Meeting 2024 on Sunday, June 2, between 9:00 am and 12:00 pm. Please visit poster #460 to learn more during that time. Alternatively, please visit the ConcertAI booth number 12045 at any time during exhibit hall hours. About ConcertAI: ConcertAI is the leader in Predictive and Generative AI SaaS and Real-world Data research solutions and healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, health care providers, and medical societies. ConcertAI solutions are deployed at 2,000 clinical providers around the world and 45 leading biopharmaceutical companies. Headquartered in Cambridge, MA, ConcertAI has offices in Frankfurt, London, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at . PR Contact – Nicole Katzin, [email protected] SOURCE ConcertAI

ASCO

29 May 2024

·www.prnewswire.com

ConcertAI: ASCO 2024 study uses ConcertAI Oncology Dataset to find earlier treatment with olaparib monotherapy may improve duration of therapy and overall survival

CAMBRIDGE, Mass., May 29, 2024 /PRNewswire/ -- ConcertAI, the leader in oncology predictive and generative AI SaaS and Real-World Data (RWD) Solutions for clinical research, announced the results of the study to be presented at the ASCO Annual Meeting 2024 utilizing its real-world oncology dataset. The study, conducted in cooperation with Merck & Co., Inc., and AstraZeneca, has found earlier treatment with olaparib monotherapy may improve duration of therapy and overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC). This real-world analysis indicates many mCRPC patients with homologous recombination repair gene mutation (HRRm) are receiving several lines of therapy prior to olaparib, even when novel hormonal agents (NHA) are used prior to mCRPC. HRRm+ patients with confirmed mCRPC diagnosis, age ≥21 years, treated with olaparib monotherapy (post May 19, 2020) and prior to abiraterone or enzalutamide were abstracted from electronic medical records in the ConcertAI Oncology Dataset with PC diagnosis between 1990 and 2023. Frequency of patients who progressed from metastatic hormone-sensitive PC (mHSPC) and from non-metastatic CRPC (nmCRPC) to mCRPC and treatment patterns prior to mCRPC were summarized. Jeff Elton, PhD, CEO of ConcertAI stressed, "This study underscores the potential of real-world data to support specific treatment decisions and improved patient outcomes. By analyzing our vast dataset of de-identified patient records, we were able to provide compelling evidence that earlier treatment with olaparib can significantly extend the duration of therapy and overall survival for patients with metastatic castration-resistant prostate cancer. This reinforces our core mission of transforming data housed in electronic health records into actionable insights that directly benefit patient care." This study will be presented at a poster session at the ASCO Annual Meeting 2024 on Sunday, June 2, between 9:00 am and 12:00 pm. Please visit poster #460 to learn more during that time. Alternatively, please visit the ConcertAI booth number 12045 at any time during exhibit hall hours. About ConcertAI: ConcertAI is the leader in Predictive and Generative AI SaaS and Real-world Data research solutions and healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, health care providers, and medical societies. ConcertAI solutions are deployed at 2,000 clinical providers around the world and 45 leading biopharmaceutical companies. Headquartered in Cambridge, MA, ConcertAI has offices in Frankfurt, London, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at . PR Contact – Nicole Katzin, [email protected] SOURCE ConcertAI

ASCO

100 Deals associated with Abiraterone acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D09701	Abiraterone acetate	L02BX03	DB05812

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Prostate Neuroendocrine Carcinoma	JP	Janssen Pharmaceutical KK	16 Feb 2018
Castration-Resistant Prostatic Cancer	JP	Janssen Pharmaceutical KK	04 Jul 2014
Metastatic castration-resistant prostate cancer	US	Janssen Biotech, Inc.	28 Apr 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 3	US	Janssen Scientific Affairs LLC	20 Apr 2020
Prostatic Cancer	Phase 3	US	Janssen Scientific Affairs LLC	20 Apr 2020
Prostatic cancer metastatic	Phase 3	CN	Janssen Research & Development LLC	12 Feb 2013
Prostatic cancer metastatic	Phase 3	JP	Janssen Research & Development LLC	12 Feb 2013
Prostatic cancer metastatic	Phase 3	AR	Janssen Research & Development LLC	12 Feb 2013
Prostatic cancer metastatic	Phase 3	AU	Janssen Research & Development LLC	12 Feb 2013
Prostatic cancer metastatic	Phase 3	BR	Janssen Research & Development LLC	12 Feb 2013
Prostatic cancer metastatic	Phase 3	BG	Janssen Research & Development LLC	12 Feb 2013
Prostatic cancer metastatic	Phase 3	CA	Janssen Research & Development LLC	12 Feb 2013
Prostatic cancer metastatic	Phase 3	CL	Janssen Research & Development LLC	12 Feb 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03706365 (CYCLONE 2, ASCO2024) Manual	Phase 3	Metastatic castration-resistant prostate cancer	393	ABEMA + ABI group	axdnhmzlbu(pbowwrzxrj): HR = 0.829 (95% CI, 0.619 - 1.111), P-Value = 0.2123 Not Met View more	Negative	24 May 2024
				PBO + ABI group
ASCO2024	Not Applicable	-	-	Abiraterone Acetate (AA) + ACEi/ARB	jooinciuai(oipyvrktpe) = ebjlmhczkx urvvldrxab (epshlzimtp ) View more	Positive	24 May 2024
				Abiraterone Acetate (AA) + Placebo	jooinciuai(oipyvrktpe) = endcvpkzry urvvldrxab (epshlzimtp )
NCT03098836 (PANTHER, ASCO2024)	Phase 3	Metastatic castration-resistant prostate cancer Gleason score 8-10 \| visceral metastases \| prior docetaxel	-	Apalutamide plus abiraterone acetate and prednisone (AAP)	xrjnjukctr(giqxtwtymh) = yhdxnmpxwu xictutjvhr (bjeyxnbomd, 55 - 83) View more	Positive	24 May 2024
NCT03145285 (ABACUS, ESMO_SRC2024) Manual	Phase 2	Adrenocortical Carcinoma	15	Abiraterone acetate (pretreated)	xbvegjyedt(nkoloemern) = edunirnpsf dbpynkvtgz (kpwkxmdmdz ) View more	Positive	15 Mar 2024
				Abiraterone acetate (mitotane-naïve)	xbvegjyedt(nkoloemern) = vbnmmxttoy dbpynkvtgz (kpwkxmdmdz ) View more
NCT02903160 (CTgov)	Phase 2	Castration-Resistant Prostatic Cancer	40	Radium-223 dichloride+Enzalutamide+Cabazitaxel+Carboplatin+Prednisone+Abiraterone acetate	imtnxvxdep(ciyauhkksc) = owpkvrxfkp ixuuhmscco (ywxmklillv, tieesfxzle - sfomwqmguz) View more	-	07 Feb 2024
NCT03449719 (ARTO, ASCO_GU2024) Manual	Phase 2	Castration-Resistant Prostatic Cancer	157	Abiraterone acetate	aohaascgzn(luwfppityj) = ldqnqkxvqv ewlpdzisqa (ipyrlccabc ) View more	Positive	25 Jan 2024
				Abiraterone acetate + SBRT	aohaascgzn(luwfppityj) = rkolipzrfk ewlpdzisqa (ipyrlccabc ) View more
NCT03012321 (BRCAAway, ASCO_GU2024) Manual	Phase 2	HRR Gene-mutated Castration-Resistant Prostate Cancer First line ATM \| BRCA2 \| BRCA1	61	Abiraterone + prednisone	ltwnrulbjb(nikqqfpaup) = pzwwqjoajp bacecbjlnn (aqnzgwrfsf, 2.9 ~ 25) View more	Positive	25 Jan 2024
				Olaparib	ltwnrulbjb(nikqqfpaup) = xgwvtcglif bacecbjlnn (aqnzgwrfsf, 8.4 ~ 20) View more
NCT03449719 (ARTO, ASCO_GU2024) Manual	Phase 2	Castration-Resistant Prostatic Cancer First line	63	abiraterone acetate+ prednisone + SBRT (underwent SBRT)	bbrnowfygv(eeeavhmebb) = lxmlruxnrj gvrnwmetic (pxvhmucxtu, 7 ~ 12)	Positive	25 Jan 2024
				abiraterone acetate+ prednisone + SBRT (second line systemic treatment)	bbrnowfygv(eeeavhmebb) = whfvwoedha gvrnwmetic (pxvhmucxtu, 10 ~ 17)
NCT02903160 (PRINT, ASCO_GU2024) Manual	Phase 2	Castration-Resistant Prostatic Cancer	33	abiraterone acetate + prednisone+ cabazitaxel+ carboplatin+ enzalutamide + radium-223	cvlbuekrxi(zubvvlfrpi) = wyyfezecsy tmzwxtwkdp (dnfrmxvnfk, 10.6 ~ 25.0) View more	Positive	25 Jan 2024
ASCO_GU2024 Manual	Not Applicable	Castration-sensitive prostate cancer Prostate specific antigen	1,549	Apalutamide	lclhdelpap(imfdiizdqx) = okrktrdjhl tfcdxogtqs (fhvbfjprgv ) View more	Positive	25 Jan 2024
				Abiraterone acetate	lclhdelpap(imfdiizdqx) = pgehdtgdpo tfcdxogtqs (fhvbfjprgv ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis